APG-157 not checked

Aveta Biomics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“APG-157 is a first-in-class investigational drug product, formulated as 100 mg soft hydrogel pastille to dissolve in the mouth”In the company’s words, NCT07667296 on ClinicalTrials.gov
Tested for
Head and Neck Cancer (2 trials), Head and Neck (HNSCC), Oropharyngeal, Oral Cavity, Oral Cavity Carcinoma, Oropharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oral Cavity and 3 more
Main trialPhase 3
“This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Two independently powered cohorts are enrolled based on treatment pathway. Cohort A evaluates APG-157 administered as neoadjuvant therapy before curative-intent surgery in participants with resectable oral cavity or oropharyngeal cancer who are medically ineligible for perioperative pembrolizumab. Cohort B evaluates APG-157 administered as induction therapy before definitive chemoradiotherapy and as maintenance therapy…”In the company’s words, NCT07667296 on ClinicalTrials.gov

Other drugs for Head and Neck Cancer

All 343 drugs for Head and Neck Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Dec 2031 APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2Active, not recruiting Dec 2026 Safety and Efficacy of APG-157 in Head and Neck Cancer
Phase 1/2Active, not recruiting 31 Dec 2026 Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow APG-157

Following is part of Solo: you see every change to APG-157 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in